407 related articles for article (PubMed ID: 26202143)
41. Serum miR-499 as a novel diagnostic and prognostic biomarker in non-small cell lung cancer.
Li M; Zhang Q; Wu L; Jia C; Shi F; Li S; Peng A; Zhang G; Song X; Wang C
Oncol Rep; 2014 Apr; 31(4):1961-7. PubMed ID: 24549225
[TBL] [Abstract][Full Text] [Related]
42. Application of plasma circulating microRNA-448, 506, 4316, and 4478 analysis for non-invasive diagnosis of lung cancer.
Powrózek T; Krawczyk P; Kowalski DM; Kuźnar-Kamińska B; Winiarczyk K; Olszyna-Serementa M; Batura-Gabryel H; Milanowski J
Tumour Biol; 2016 Feb; 37(2):2049-55. PubMed ID: 26341493
[TBL] [Abstract][Full Text] [Related]
43. Usefulness of Plasma Exosomal MicroRNA-451a as a Noninvasive Biomarker for Early Prediction of Recurrence and Prognosis of Non-Small Cell Lung Cancer.
Kanaoka R; Iinuma H; Dejima H; Sakai T; Uehara H; Matsutani N; Kawamura M
Oncology; 2018; 94(5):311-323. PubMed ID: 29533963
[TBL] [Abstract][Full Text] [Related]
44. Diagnostic and prognostic value of plasma microRNA-195 in patients with non-small cell lung cancer.
Su K; Zhang T; Wang Y; Hao G
World J Surg Oncol; 2016 Aug; 14(1):224. PubMed ID: 27733164
[TBL] [Abstract][Full Text] [Related]
45. Circulating miR-125b is a novel biomarker for screening non-small-cell lung cancer and predicts poor prognosis.
Yuxia M; Zhennan T; Wei Z
J Cancer Res Clin Oncol; 2012 Dec; 138(12):2045-50. PubMed ID: 22806310
[TBL] [Abstract][Full Text] [Related]
46. A serum microRNA classifier for early detection of hepatocellular carcinoma: a multicentre, retrospective, longitudinal biomarker identification study with a nested case-control study.
Lin XJ; Chong Y; Guo ZW; Xie C; Yang XJ; Zhang Q; Li SP; Xiong Y; Yuan Y; Min J; Jia WH; Jie Y; Chen MS; Chen MX; Fang JH; Zeng C; Zhang Y; Guo RP; Wu Y; Lin G; Zheng L; Zhuang SM
Lancet Oncol; 2015 Jul; 16(7):804-15. PubMed ID: 26088272
[TBL] [Abstract][Full Text] [Related]
47. miR-638 is a new biomarker for outcome prediction of non-small cell lung cancer patients receiving chemotherapy.
Wang F; Lou JF; Cao Y; Shi XH; Wang P; Xu J; Xie EF; Xu T; Sun RH; Rao JY; Huang PW; Pan SY; Wang H
Exp Mol Med; 2015 May; 47(5):e162. PubMed ID: 25952770
[TBL] [Abstract][Full Text] [Related]
48. Peripheral blood miR-328 expression as a potential biomarker for the early diagnosis of NSCLC.
Ulivi P; Foschi G; Mengozzi M; Scarpi E; Silvestrini R; Amadori D; Zoli W
Int J Mol Sci; 2013 May; 14(5):10332-42. PubMed ID: 23681013
[TBL] [Abstract][Full Text] [Related]
49. Serum exosomal microRNAs as predictive markers for EGFR mutations in non-small-cell lung cancer.
Xia J; Luo M; Dai L; Wang L; Wang L; Zhu J
J Clin Lab Anal; 2021 May; 35(5):e23743. PubMed ID: 33682961
[TBL] [Abstract][Full Text] [Related]
50. Circulating microRNA array (miR-182, 200b and 205) for the early diagnosis and poor prognosis predictor of non-small cell lung cancer.
Zou JG; Ma LF; Li X; Xu FL; Fei XZ; Liu Q; Bai QL; Dong YL
Eur Rev Med Pharmacol Sci; 2019 Feb; 23(3):1108-1115. PubMed ID: 30779079
[TBL] [Abstract][Full Text] [Related]
51. Identification of a three-miRNA signature as a blood-borne diagnostic marker for early diagnosis of lung adenocarcinoma.
Wang Y; Zhao H; Gao X; Wei F; Zhang X; Su Y; Wang C; Li H; Ren X
Oncotarget; 2016 May; 7(18):26070-86. PubMed ID: 27036025
[TBL] [Abstract][Full Text] [Related]
52. Longitudinal study on circulating miRNAs in patients after lung cancer resection.
Leidinger P; Galata V; Backes C; Stähler C; Rheinheimer S; Huwer H; Meese E; Keller A
Oncotarget; 2015 Jun; 6(18):16674-85. PubMed ID: 26078336
[TBL] [Abstract][Full Text] [Related]
53. Serum miR-142-3p is associated with early relapse in operable lung adenocarcinoma patients.
Kaduthanam S; Gade S; Meister M; Brase JC; Johannes M; Dienemann H; Warth A; Schnabel PA; Herth FJ; Sültmann H; Muley T; Kuner R
Lung Cancer; 2013 May; 80(2):223-7. PubMed ID: 23410826
[TBL] [Abstract][Full Text] [Related]
54. Identification of plasma microRNAs as novel noninvasive biomarkers for early detection of lung cancer.
Tang D; Shen Y; Wang M; Yang R; Wang Z; Sui A; Jiao W; Wang Y
Eur J Cancer Prev; 2013 Nov; 22(6):540-8. PubMed ID: 23462458
[TBL] [Abstract][Full Text] [Related]
55. Serum microRNA signatures identified in a genome-wide serum microRNA expression profiling predict survival of non-small-cell lung cancer.
Hu Z; Chen X; Zhao Y; Tian T; Jin G; Shu Y; Chen Y; Xu L; Zen K; Zhang C; Shen H
J Clin Oncol; 2010 Apr; 28(10):1721-6. PubMed ID: 20194856
[TBL] [Abstract][Full Text] [Related]
56. Low levels of cell-free circulating miR-361-3p and miR-625* as blood-based markers for discriminating malignant from benign lung tumors.
Roth C; Stückrath I; Pantel K; Izbicki JR; Tachezy M; Schwarzenbach H
PLoS One; 2012; 7(6):e38248. PubMed ID: 22675530
[TBL] [Abstract][Full Text] [Related]
57. Low serum miR-98 as an unfavorable prognostic biomarker in patients with non-small cell lung cancer.
Wang K; Dong L; Fang Q; Xia H; Hou X
Cancer Biomark; 2017 Sep; 20(3):283-288. PubMed ID: 28946561
[TBL] [Abstract][Full Text] [Related]
58. Sputum microRNA profiling: a novel approach for the early detection of non-small cell lung cancer.
Roa WH; Kim JO; Razzak R; Du H; Guo L; Singh R; Gazala S; Ghosh S; Wong E; Joy AA; Xing JZ; Bedard EL
Clin Invest Med; 2012 Oct; 35(5):E271. PubMed ID: 23043708
[TBL] [Abstract][Full Text] [Related]
59. Serum miRNAs associated with tumor-promoting cytokines in non-small cell lung cancer.
Chaniad P; Trakunran K; Geater SL; Keeratichananont W; Thongsuksai P; Raungrut P
PLoS One; 2020; 15(10):e0241593. PubMed ID: 33125430
[TBL] [Abstract][Full Text] [Related]
60. Clinical Significance of Circulatory miRNA-21 as an Efficient Non-Invasive Biomarker for the Screening of Lung Cancer Patients.
Abu-Duhier FM; Javid J; Sughayer MA; Mir R; Albalawi T; Alauddin MS
Asian Pac J Cancer Prev; 2018 Sep; 19(9):2607-2611. PubMed ID: 30256067
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
